Summary
BRANSONPHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €174,472 and a net result of €30,298. Equity is growing by about 24% per year across the filed financial years. Its solvency ranks better than 21% of 9,727 sector peers (NACE 64, financial year 2025). The company has been active since 2005 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Connections & network
No directors read yet: 1 of 3 Gazette acts processed.